Arrowsmith J - Search Results

1

Trial watch: phase II and phase III attrition rates 2011-2012.

Arrowsmith J, Miller P. Arrowsmith J, et al. Nat Rev Drug Discov. 2013 Aug;12(8):569. doi: 10.1038/nrd4090. Nat Rev Drug Discov. 2013. PMID: 23903212 No abstract available.

2

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival.

Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, Street SD. Morgan P, et al. Among authors: arrowsmith j. Drug Discov Today. 2012 May;17(9-10):419-24. doi: 10.1016/j.drudis.2011.12.020. Epub 2011 Dec 29. Drug Discov Today. 2012. PMID: 22227532

3

An analysis of the attrition of drug candidates from four major pharmaceutical companies.

Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, Pairaudeau G, Pennie WD, Pickett SD, Wang J, Wallace O, Weir A. Waring MJ, et al. Among authors: arrowsmith j. Nat Rev Drug Discov. 2015 Jul;14(7):475-86. doi: 10.1038/nrd4609. Epub 2015 Jun 19. Nat Rev Drug Discov. 2015. PMID: 26091267 Review.

4

Trial watch: phase III and submission failures: 2007-2010.

Arrowsmith J. Arrowsmith J. Nat Rev Drug Discov. 2011 Feb;10(2):87. doi: 10.1038/nrd3375. Nat Rev Drug Discov. 2011. PMID: 21283095 No abstract available.

5

Trial watch: Phase II failures: 2008-2010.

Arrowsmith J. Arrowsmith J. Nat Rev Drug Discov. 2011 May;10(5):328-9. doi: 10.1038/nrd3439. Nat Rev Drug Discov. 2011. PMID: 21532551 No abstract available.

6

A decade of change.

Arrowsmith J. Arrowsmith J. Nat Rev Drug Discov. 2012 Jan 3;11(1):17-8. doi: 10.1038/nrd3630. Nat Rev Drug Discov. 2012. PMID: 22212671 No abstract available.

7

Orphan drug development: an economically viable strategy for biopharma R&D.

Meekings KN, Williams CS, Arrowsmith JE. Meekings KN, et al. Drug Discov Today. 2012 Jul;17(13-14):660-4. doi: 10.1016/j.drudis.2012.02.005. Epub 2012 Feb 17. Drug Discov Today. 2012. PMID: 22366309

8

Deliberating Upon the Living Wage to Alleviate In-Work Poverty: A Rhetorical Inquiry Into Key Stakeholder Accounts.

Hodgetts DJ, Young-Hauser AM, Arrowsmith J, Parker J, Carr SC, Haar J, Alefaio S. Hodgetts DJ, et al. Among authors: arrowsmith j. Front Psychol. 2022 Jun 3;13:810870. doi: 10.3389/fpsyg.2022.810870. eCollection 2022. Front Psychol. 2022. PMID: 35719495 Free PMC article.

9

Pandemic or Not, Worker Subjective Wellbeing Pivots About the Living Wage Point: A Replication, Extension, and Policy Challenge in Aotearoa New Zealand.

Carr SC, Haar J, Hodgetts D, Jones H, Arrowsmith J, Parker J, Young-Hauser A, Alefaio S. Carr SC, et al. Among authors: arrowsmith j. Front Psychol. 2022 May 17;13:828081. doi: 10.3389/fpsyg.2022.828081. eCollection 2022. Front Psychol. 2022. PMID: 35656490 Free PMC article.

10

Optimal protamine dosing after cardiopulmonary bypass: The PRODOSE adaptive randomised controlled trial.

Miles LF, Burt C, Arrowsmith J, McKie MA, Villar SS, Govender P, Shaylor R, Tan Z, De Silva R, Falter F. Miles LF, et al. Among authors: arrowsmith j. PLoS Med. 2021 Jun 7;18(6):e1003658. doi: 10.1371/journal.pmed.1003658. eCollection 2021 Jun. PLoS Med. 2021. PMID: 34097705 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results